Pharmaceutical intermediates Proglumide raw powder supplier

CAS: 6620-60-6

MF: C18H26N2O4

MW: 334.41

EINECS: 229-567-4

Specification: 99% min Proglumide powder

Sample: Proglumide powder Avaliable

Packaging: 1kg/bag, 25kg/drum

Brand: Ausreson

MOQ: 1 kg

Appearance: white powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Last updated: March 2026

Proglumide powder Usage and Synthesis.

Dipropanglutamide is used for gastric and duodenal ulcers, gastritis (e.g. chronic superficial gastritis), and duodenoculitis.

1. Combined with other anti-ulcer drugs (such as H2 receptor antagonists), it can enhance the effect of inhibiting gastric acid secretion and accelerate ulcer healing.

2. When used in combination with morphine, it can enhance the analgesic effect of morphine and prolong the duration of its effect.

3. This product can antagonize the effect of haloperidol to aggravate movement disorders, so the two can not be used in the treatment of Huntington's disease.

How Proglumide Targets the Gut-Brain Axis

• Competitive Gastrin Antagonism: Proglumide competes with gastrin for receptor sites on parietal cells. In 2026, it is used to inhibit gastric acid secretion, providing a non-PPI (Proton Pump Inhibitor) alternative for managing Gastric and Duodenal Ulcers.

• CCK-A & CCK-B Inhibition: As a non-selective CCK antagonist, it blocks the hormones that can interfere with pain modulation. In 2026, it is a primary research focus for preventing or reversing opioid tolerance, allowing for lower effective doses and reduced side effects.

• Trophic Effect Inhibition: By blocking gastrin, it inhibits the overgrowth of certain gastrointestinal cells, making it a critical 2026 tool for studying the prevention of gastrin-dependent hyperplasias.

• Biliary & Pancreatic Regulation: It reduces pancreatic enzyme secretion and gallbladder contraction, offering a specialized approach to managing post-prandial discomfort in complex GI cases.

Uses of Proglumide.

Dipropanglutamide is a gastrin receptor antagonist, which can protect gastric mucosa and promote ulcer healing. Suitable for gastric and duodenal ulcer, gastritis, stress ulcer, the effective rate of 81-96%, the application of this product does not occur the increase of gastric acid rebound, and the recurrence rate is low. It is a gastrin receptor antagonist for gastric and duodenal ulcer disease.

Why "99% Pure Crystalline Isolate" is the 2026 Standard

1. High Molecular Precision: In 2026, pharmaceutical-grade 99% Pure Proglumide Powder is required for consistent bio-activity. This purity ensures that the competitive antagonism at the receptor level is not hindered by manufacturing by-products.

2. Solubility in Organic Solvents: Premium 2026 powders are engineered for optimal solubility in varied carriers, facilitating its use in both oral formulations and advanced laboratory research environments.

3. Zero-Moisture Packaging: Because Proglumide can be sensitive to environmental humidity, the 2026 gold standard involves Vacuum-Sealed Aluminum Foil packaging to prevent degradation and ensure a 24-month+ shelf life.

Pharmacological action of Proglumide.

This product is an antagonist of cholecystokinin receptor and gastrin receptor, and its molecular structure is similar to the terminal molecular structure of gastrin (G-17) and cholecystokinin (CCK), so the functional group amyl group can specifically compete with G-17 on the G-17 receptor in parietal cells, and significantly inhibit the secretion of gastric acid and pepsin caused by G-17. Increase the content of hexosamine in gastric mucosa, promote glycoprotein synthesis, protect gastric mucosa, thus improve the symptoms of peptic ulcer and promote ulcer healing. The inhibitory effect of this product on gastric acid secretion caused by histamine and vagus nerve stimulation is not obvious, and the rebound phenomenon of gastric acid secretion does not occur in the treatment of peptic ulcer and gastritis, and the gastric acid secretion can still be at the normal level for half a year after the termination of treatment. Because of its weaker inhibition of gastric acid secretion than H2 receptor antagonists, it is no longer used in the treatment of ulcer disease alone in clinic, but its gallbladder effect has been paid more attention recently.

The 2026 "Pharma-Pure" Checklist

• ≥ 99.0% Purity (HPLC/Titration Verified): The non-negotiable threshold for research and pharmaceutical applications.

• Heavy Metal Compliance: Strictly tested for Lead, Arsenic, and Mercury ($<10 ppm$) to meet 2026 global safety standards.

• Clean Synthesis Profile: Verified absence of residual catalysts like palladium or specific organic solvents (Hexane-free).

• Comprehensive COA: Every batch must include a Certificate of Analysis detailing melting point, LOD (Loss on Drying), and ash content.

Product Methods of Proglumide.

Glutamic acid is used as the starting material to obtain N-benzoyl glutamic acid by reacting with benzoyl chloride, and then reacting with acetic anhydride to obtain N-benzoyl glutamic anhydride, and then aminating with dipropylamine to obtain proglumine. The total yield was 26-30% as measured by glutamic acid.

Frequently Asked Questions

No. In 2026, we clarify: PPIs shut down the acid pumps directly. Proglumide is a receptor antagonist that blocks the signal (gastrin) that tells the pumps to start. This makes it a more targeted "upstream" intervention.

Clinical research in 2026 highlights that CCK acts as an "anti-opioid." By blocking CCK receptors with Proglumide powder, the body's natural (or supplemental) pain-relief signaling remains active longer, potentially delaying the onset of drug tolerance.

For gastrointestinal support, doses typically range from 200mg to 400mg, taken three times daily before meals. For research purposes regarding tolerance, dosages are strictly titrated based on individual protocol requirements.

Proglumide is generally well-tolerated in 2026 protocols, though rare side effects can include dry mouth or mild skin rashes. Always consult a specialist for long-term use.

Поставщик сырья для фармацевтических интермедиатов проглумида в порошке
Fournisseur de poudre brute d'intermédiaires pharmaceutiques Proglumide
Lieferant von pharmazeutischen Zwischenprodukten für Proglumid-Rohpulver
Proveedor de materia prima en polvo de Proglumida para intermediarios farmacéuticos
Fornecedor de matéria-prima em pó de Proglumida para intermediários farmacêuticos